USFDA visit to Alembic Pharmaceuticals Panelav facility

None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable

Bhushan Akshikar appointed MD of GlaxoSmithKline Pharmaceuticals

He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry

Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan

Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)

Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals

DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.

ENTOD Pharmaceuticals organises eye donation awareness campaign

The #pledgemyeyes initiative reached out to over 30 million people across the country and the website registered 3X more pledges compared to the present numbers

Avery Pharmaceuticals starts commercial production of unit at Sanand

The plant is a dedicated for manufacturing of Mouth dissolving strip.

USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi

Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets

Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA

Alembic Pharmaceuticals completes USFDA RRA for its bioequivalence facility

The RRA was conducted from 22nd August, 2022 to 26th August, 2022.

Alembic Pharmaceuticals receives USFDA final approval for Chlorthalidone Tablets USP

he approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Hygroton Tablets, 25 mg and 50 mg, of Sanofi Aventis US. LLC (Sanofi).